Dapoxetine
- Generic Name
- Dapoxetine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23NO
- CAS Number
- 119356-77-3
- Unique Ingredient Identifier
- GB2433A4M3
- Background
Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation in De...
- Indication
For the treatment of premature ejaculation.
- Associated Conditions
- Premature Ejaculation
- Associated Therapies
- -
Observational Study of Pharmacological Treatment for Premature Ejaculation Concurrent With Erectile Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Yan-Ping Huang
- Target Recruit Count
- 150
- Registration Number
- NCT04361305
Evaluation of the Clinical Efficacy and Safety of Dapoxetine, Combined Dapoxetine With Folic Acid and Combined Dapoxetine With Vitamin B12 in Treatment of Patients With Premature Ejaculation
- Conditions
- Interventions
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Sohag University
- Target Recruit Count
- 120
- Registration Number
- NCT04085354
- Locations
- 🇪🇬
Faculty of Medicine, Sohag University, Egypt, Sohag, Egypt
Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation
- Conditions
- Interventions
- First Posted Date
- 2017-01-12
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Pusan National University Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT03018743
- Locations
- 🇰🇷
Department of Urology, Pusan National University Hospital, Busan, Korea, Republic of
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine
- Conditions
- Interventions
- First Posted Date
- 2013-08-26
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Dong-A Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT01928563
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of
Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044
- First Posted Date
- 2011-08-18
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT01419470
- Locations
- 🇰🇷
Samsung medical center, Seoul, Korea, Republic of
An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation
- Conditions
- Interventions
- First Posted Date
- 2010-10-29
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Alza Corporation, DE, USA
- Target Recruit Count
- 1774
- Registration Number
- NCT01230762
The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy
- First Posted Date
- 2010-02-05
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 285
- Registration Number
- NCT01063881
Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2010-02-05
- Last Posted Date
- 2013-01-24
- Target Recruit Count
- 495
- Registration Number
- NCT01063855
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
- Conditions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 1116
- Registration Number
- NCT00229073
A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 1067
- Registration Number
- NCT00210704
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.